Shah Capital has ended its attempts to exert influence over vaccine developer Novavax, bringing more than years of activism and pressure on management to an end. The change in policy – reported by ...

Oct 16 (Reuters) - Shah Capital, one of Novavax's (NVAX.O), opens new tab top shareholders, said on Friday it no longer seeks to influence ‌control of the vaccine maker after restructuring into a ...

Vaccine stocks are under heavy pressure, and the smallest name in the group is taking the heaviest losses. Novavax (NASDAQ:NVAX) stock is down 12% to $11.23 in afternoon trading, leading the slide ...

A protein-vaccine developer with no fresh catalyst just posted a double-digit gain that dwarfs what Moderna and Merck managed in the same session, and the explanation reveals something uncomfortable ...